Bromocriptine and Prostatic Carcinoma: Plasma Kinetics, production and Tissue Uptake of3H-Testosterone in Vivo

Abstract
The influence of the antiprolactin bromocriptine on plasma kinetics, production rate and tissue uptake of testosterone was investigated in 15 patients with newly diagnosed stage C and D prostatic carcinoma. Bromocriptine was given for 5 days in a daily dose of 15 mg orally. The studies were performed with the single injection technique using the 2-compartment model. Plasma testosterone, serum prolactin luteinizing and follicle-stimulating hormones were determined initially. Blood samples were drawn up to 5 h after injection of 3H-testosterone. For tissue studies a transrectal needle biopsy was done 3 h postinjection. Bromocriptine suppressed prolactin and the endogenous testosterone level. It favored the elimination of 3H-testosterone, lowered the production rate of testosterone and hampered in vivo uptake of the 3H-label into prostatic carcinoma tissue. The grading of the tumor lesions affected only the prebromocriptine uptake of radioactive androgens and not uptake in response to bromocriptine. The potential clinical implications of these observations are discussed.

This publication has 15 references indexed in Scilit: